Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Northwest Biotherapeutics (NWBO) Leases (2019 - 2025)

Northwest Biotherapeutics' Leases history spans 7 years, with the latest figure at $4.2 million for Q4 2025.

  • Quarterly results put Leases at $4.2 million for Q4 2025, changed 0.24% from a year ago — trailing twelve months through Dec 2025 was $4.2 million (changed 0.24% YoY), and the annual figure for FY2025 was $4.2 million, changed 0.24%.
  • Leases for Q4 2025 was $4.2 million at Northwest Biotherapeutics, down from $4.3 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $5.1 million in Q1 2021 to a low of $4.0 million in Q3 2022.
  • The 5-year median for Leases is $4.2 million (2023), against an average of $4.4 million.
  • The sharpest move saw Leases increased 20.4% in 2021, then dropped 18.85% in 2022.
  • Year by year, Leases stood at $4.9 million in 2021, then dropped by 14.32% to $4.2 million in 2022, then decreased by 0.14% to $4.2 million in 2023, then increased by 0.1% to $4.2 million in 2024, then increased by 0.24% to $4.2 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $4.2 million, $4.3 million, and $4.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.